Incidence of genes encoding vanA/vanB vancomycin resistance in rectal swabs of patients with diagnosed cancer, on the day of admission to hospital, in a non-epidemic period.
colonisation
oncological patients
vanA/vanB enterococci
Journal
Przeglad gastroenterologiczny
ISSN: 1895-5770
Titre abrégé: Prz Gastroenterol
Pays: Poland
ID NLM: 101280380
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
07
2019
accepted:
20
09
2019
entrez:
2
10
2020
pubmed:
3
10
2020
medline:
3
10
2020
Statut:
ppublish
Résumé
Rapid diagnosis is important for preventing infections due to vancomycin-resistant enterococci. To evaluate the status of gastrointestinal colonisation with strains containing vanA/vanB genes in oncological patients. A total of 167 samples of rectal swabs taken from 161 patients (mean age: 63, range: 29-93 years) were examined, including 113 patients from surgical wards (70.2%) and 48 patients from non-surgical wards (29.8%), with diagnosed cancer. The tests were carried out within 24 h of admitting the patient to the department, using the Cepheid Xpert vanA/vanB test, with a CE marked GeneXpert The presence of the vanA gene was found in 2.7% and 6.3% of the examined patients, respectively, from the surgical and non-surgical departments, which accounted for 3.7% of all the patients examined. The presence of the vanB gene was detected in 21.1% of the patients, but in no case was there any growth of vancomycin-resistant enterococci on the chromogenic medium. Patients admitted to non-surgical wards were more often colonised with vanA/vanB genes than were patients admitted to surgical wards, but the differences were not statistically significant.
Identifiants
pubmed: 33005267
doi: 10.5114/pg.2020.98537
pii: 41689
pmc: PMC7509899
doi:
Types de publication
Journal Article
Langues
eng
Pagination
220-224Informations de copyright
Copyright © 2020 Termedia.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Lancet. 2001 Mar 17;357(9259):855-6
pubmed: 11265957
Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S104-10
pubmed: 25486947
Euro Surveill. 2008 Nov 20;13(47):
pubmed: 19021959
Am J Infect Control. 2006 Oct;34(8):534-6
pubmed: 17015161
Int J Antimicrob Agents. 2017 May;49(5):565-572
pubmed: 28336313
Infect Drug Resist. 2015 Jul 24;8:217-30
pubmed: 26244026
Antimicrob Resist Infect Control. 2017 May 16;6:48
pubmed: 28515904
New Microbes New Infect. 2017 Jan 12;16:54-59
pubmed: 28203378
J Lab Physicians. 2018 Jan-Mar;10(1):89-94
pubmed: 29403213
Eur J Clin Microbiol Infect Dis. 2012 Mar;31(3):273-6
pubmed: 21667270
Antonie Van Leeuwenhoek. 2012 Mar;101(3):671-5
pubmed: 22124681
Eur J Clin Microbiol Infect Dis. 2017 May;36(5):823-829
pubmed: 27987047
J Clin Diagn Res. 2016 Sep;10(9):DC06-DC09
pubmed: 27790430
Infection. 2013 Oct;41(5):1039-40
pubmed: 23475503
Infection. 2012 Dec;40(6):613-9
pubmed: 22665143